← BioAtla, Inc. (BCAB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BioAtla, Inc. (BCAB)
Biological Products, (No Diagnostic Substances) · market cap $2M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 2
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
BioAtla, Inc. (BCAB) is a clinical-stage biotech with a multi-asset ADC and oncology pipeline spanning sarcoma and NSCLC, anchored by its lead CAB-AXL-ADC in Phase 2 for Undifferentiated Pleomorphic Sarcoma. At a $123M market cap with only ~$2M cash and an estimated 1.1-month runway, the company faces an acute near-term financing crisis that dominates all other considerations. No revenue has been generated in any reported fiscal year.
The catalyst path
- 2026-12-31 (est.)Phase 2 · BA3011imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CAB-AXL-ADC | Phase 2 | Undifferentiated Pleomorphic Sarcoma |
| BA3071 | Phase 2 | NSCLC |
| CAB-ROR2-ADC | Phase 2 | Non Small Cell Lung Cancer |
| Ozuriftamab Vedotin | Phase 2 | Head and Neck Cancer |
| PD-1 inhibitor | Phase 2 | Non-Small-Cell Lung Cancer |
| BA3011 | Phase 2 | Ovarian Cancer |
Price & technical context
3-month
-69.9%
6-month
-81.3%
12-month
-96.3%
52-wk range
$1.08–$61.00
vs 50-day MA
-48.4%
vs 200-day MA
-84.3%
Realized vol
165.4%
Max drawdown
-99.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BCAB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.